AntiTNF-α agents in the treatment of inflammation

Expert Opinion on Investigational Drugs

Volumn 7, Issue 11, 1998, Pages 1825-1839

  Sekut, L ^a   Connolly, K ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Inflammatory bowel disease; Inflammatory disease; Lymphotoxin; Multiple sclerosis; Rheumatoid arthritis; Tumour necrosis factor alpha; Tumour necrosis factor alpha inhibitor

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; LYMPHOTOXIN; MATRIX METALLOPROTEINASE; PHOSPHODIESTERASE IV; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CELL KILLING; CELL PROLIFERATION; CELL TYPE; CLONE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG COST; ENTERITIS; IMMUNOGENICITY; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MULTIPLE SCLEROSIS; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL;

EID: 0031789652     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.7.11.1825     Document Type: Review

References (100)